Global Celiac Disease Drugs Market 2017-2021

  • ID: 4319122
  • Report
  • Region: Global
  • 76 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer
  • Biotest
  • Celimmune
  • Immunomedics
  • Kedrion Biopharma
  • MORE

About Celiac Disease Drugs

Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other sources through our food. Presently, there is no specific drug approved for celiac disease, and the first line of treatment is completely dominated by a gluten-free diet. There are few anti-inflammatory and immunosuppressant drugs and nutritional supplements that are used as off-label therapy in celiac disease. All these off-label therapies are considered as second-line of treatment.

The analysts forecast the global celiac disease drugs market to grow at a CAGR of 24.22% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global celiac disease drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Celiac Disease Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Pfizer

Other prominent vendors

  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer
  • Biogen
  • BioLineRx
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Celimmune
  • ImmunogenX
  • Immunomedics
  • ImmusanT
  • Innovate Biopharmaceuticals
  • Kedrion Biopharma
  • LFB Group
  • Novartis
  • Shire
  • Takeda Pharmaceutical

Market drivers

  • Prevalence of disease
  • For a full, detailed list, view the full report

Market challenges

  • Long-term sustainability
  • For a full, detailed list, view the full report

Market trends

  • Inorganic growth strategies
  • For a full, detailed list, view the full report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer
  • Biotest
  • Celimmune
  • Immunomedics
  • Kedrion Biopharma
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of celiac disease

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by therapy type
  • First line of treatment
  • Second line of treatment
PART 09: Geographical segmentation
  • Celiac disease drugs market in Americas
  • Celiac disease drugs market in EMEA
  • Celiac disease drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Inorganic growth strategies
  • Robust pipeline
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Stage 1: Initiation process in celiac disease
Exhibit 02: Stage 2: Triggering phase in celiac disease
Exhibit 03: Diagnostic approach for celiac disease
Exhibit 04: Global celiac disease drugs market snapshot
Exhibit 05: Global celiac disease drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global celiac disease treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline analysis of key molecules for celiac disease
Exhibit 09: Key clinical trials: Celiac disease drugs 2016
Exhibit 10: Segmentation of global celiac disease drugs market by therapy type 2016
Exhibit 11: Global celiac disease first line of treatment market 2016-2021 ($ millions)
Exhibit 12: Various drug classes used in second line of treatment of celiac disease
Exhibit 13: Global celiac disease second line of treatment market 2016-2021 ($ millions)
Exhibit 14: Segmentation of global celiac disease drugs market by geography 2016 and 2021
Exhibit 15: Segmentation of global celiac disease drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 16: Market scenario in Americas
Exhibit 17: Celiac disease drugs market in Americas 2016-2021 ($ millions)
Exhibit 18: Market scenario in EMEA
Exhibit 19: Celiac disease drugs market in EMEA 2016-2021 ($ millions)
Exhibit 20: Market Scenario in APAC
Exhibit 21: Celiac disease drugs market in APAC 2016-2021 ($ millions)
Exhibit 22: Widely consumed foods containing gluten
Exhibit 23: The consumption rate of beer in US 2011-2015
Exhibit 24: Government initiatives by various countries for celiac disease
Exhibit 25: Various symptoms associated with celiac disease
Exhibit 26: Factors affecting long-term sustainability of gluten-free diet
Exhibit 27: Inorganic growth strategies for global celiac disease drugs market
Exhibit 28: Competitive structure analysis of global celiac disease drugs market 2016
Exhibit 29: Competitive factors of global celiac disease drugs market
Exhibit 30: Market penetration of various celiac disease drugs manufacturers worldwide 2016
Exhibit 31: Strategic success factors of companies in global celiac disease drugs market
Exhibit 32: F. Hoffmann-La Roche: Key highlights
Exhibit 33: F. Hoffmann-La Roche: Strength assessment
Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 36: Johnson & Johnson: Key highlights
Exhibit 37: Johnson & Johnson: Strength assessment
Exhibit 38: Johnson & Johnson: Strategy assessment
Exhibit 39: Johnson & Johnson: Opportunity assessment
Exhibit 40: Merck: Key highlights
Exhibit 41: Merck: Strength assessment
Exhibit 42: Merck Strategy assessment
Exhibit 43: Merck: Opportunity assessment
Exhibit 44: Pfizer: Key highlights
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ADMA Biologics
  • Bayer
  • Biotest
  • Celimmune
  • Immunomedics
  • Kedrion Biopharma
  • MORE
New Report Released: – Global Celiac Disease Drugs market 2017-2021

The author of the report recognizes the following companies as the key players in the global celiac disease drugs market: F. Hoffmann-La Roche, Johnson & Johnson, Merck, and Pfizer.

Other Prominent Vendors in the market are: ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, Biotest, Bristol-Myers Squibb, Celgene, Celimmune, ImmunogenX, Immunomedics, ImmusanT, Innovate Biopharmaceuticals, Kedrion Biopharma, LFB Group, Novartis, Shire, and Takeda Pharmaceutical.

Commenting on the report, an analyst from the research team said: “One trend in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute to the growth of the global celiac disease drugs market. These inorganic growth strategies include global mergers and acquisitions (M&A), partnerships, and regional acquisitions.”

According to the report, one driver in the market is prevalence of disease. Celiac disease is an autoimmune disease in which the immune system is triggered due to ingestion of gluten and damages inner lining of the small intestine. This leads to various consequences associated with it. The prevalence of the disease is high and expected to remain high in future due to dependence on gluten-containing food and no specific drug to treat this disease. The only option available till date is consumption of gluten-free diet along with some off-label usage based on the symptoms.

Further, the report states that one challenge in the market is long-term sustainability. A gluten-free diet is currently an only available option for the treatment of celiac disease. A gluten-free diet is the only way to improve the quality of life for individuals suffering from this disease. The individuals must be dependent on this food for a long period, because the moment they switch to gluten food, the immune response can trigger again.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer
  • Biogen
  • BioLineRx
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Celimmune
  • F Hoffmann-La Roche
  • ImmunogenX
  • Immunomedics
  • ImmusanT
  • Innovate Biopharmaceuticals
  • Johnson & Johnson
  • Kedrion Biopharma
  • LFB Group
  • Merck
  • Novartis
  • Pfizer
  • Shire
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll